Newfound Research’s iShares Global Healthcare ETF IXJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-46,378
Closed -$3.19M 121
2020
Q2
$3.19M Buy
46,378
+33,271
+254% +$2.25M 3.97% 8
2020
Q1
$799K Sell
13,107
-58,307
-82% -$3.84M 0.89% 9
2019
Q4
$4.91M Sell
71,414
-12,727
-15% -$825K 4.61% 1
2019
Q3
$5.14M Buy
84,141
+61,920
+279% +$3.79M 4.51% 2
2019
Q2
$1.37M Sell
22,221
-50,584
-69% -$3.03M 1.19% 34
2019
Q1
$4.45M Sell
72,805
-34,866
-32% -$2.08M 3.24% 15
2018
Q4
$6.1M Sell
107,671
-31,914
-23% -$1.91M 4.23% 5
2018
Q3
$8.79M Buy
+139,585
New +$8.43M 4.99% 5
2018
Q1
Sell
-97,638
Closed -$5.49M 208
2017
Q4
$5.49M Sell
97,638
-7,970
-8% -$448K 2.92% 13
2017
Q3
$5.94M Buy
105,608
+14,268
+16% +$785K 3.4% 10
2017
Q2
$4.99M Buy
91,340
+31,716
+53% +$1.69M 3.49% 10
2017
Q1
$3.06M Buy
+59,624
New +$2.98M 2.39% 16
2016
Q4
Sell
-103,336
Closed -$5.21M 160
2016
Q3
$5.21M Buy
103,336
+52,368
+103% +$2.69M 4.96% 10
2016
Q2
$2.57M Buy
+50,968
New +$2.54M 2.69% 13

Other funds holding IXJ

Newfound Research's IXJ Position: Q3 2020 in Review

Newfound Research sold out of iShares Global Healthcare ETF (IXJ) in Q3 2020, closing a stake of 46,378 shares — an estimated $3.19M sold.

Newfound Research first reported a position in IXJ in Q2 2016 and held it in 14 quarters. The position peaked at $8.79M in Q3 2018. 198 funds tracked by Wall St. Rank hold IXJ as of Q3 2020.

  • Newfound Research reported no remaining iShares Global Healthcare ETF position as of Q3 2020 after selling out during the quarter.
  • Newfound Research sold 46,378 iShares Global Healthcare ETF shares in Q3 2020, an estimated $3.19M.
  • Newfound Research first reported a position in iShares Global Healthcare ETF in Q2 2016 and held it in 14 quarters.
  • Newfound Research's iShares Global Healthcare ETF position peaked at $8.79M in Q3 2018.
  • 198 funds tracked by Wall St. Rank held iShares Global Healthcare ETF as of Q3 2020.

Based on Newfound Research's 13F filing for Q3 2020, filed 20 Oct 2020.